Serhan YILDIRIM, Zahide YILMAZ, Ülkü Türk BÖRÜ

Evaluation of Stroke Frequency in Non-Small Cell Lung Cancer Patients Receiving Cisplatin and Docetaxel

INTRODUCTION: Stroke refers to a clinical condition following cerebrovascular disease and a sudden neurological failure. It's divided into two subgroups according to damage pathology. Cisplatin and docetaxel are drugs used in various cancer treatments. In this study, we aimed to investigate the frequency of stroke in non-small cell lung cancer patients receiving docetaxel with cisplatin during and after the therapy METHODS: Patients, over 18 diagnosed with non-small cell lung cancer and receiving at least six therapies of docetaxel(75mg/m2) and cisplatin(75mg/m2) in every 21 days, were monitored prospectively in Medical Oncology Clinique for 6 months. Patients were questioned when they were diagnosed with cancer and if they have metastases, then the neurological examination was performed. When the drug treatment was completed, the patients were questioned as to whether they experienced stroke during or after the therapy. If they experienced stroke, its type (hemorrhagic / ischemic) was examined. RESULTS: During the follow-up period, ischemic stroke developed in six (3%) of the patients. Four of these patients(2.3%) were male, two (7.7%) were female. Lymph node metastasis in 61 (31 %) patients, brain metastasis in 25 (12.7%), bone metastasis in 24 (12.2%), surrenal metastasis in 7 (3.6 %) and liver metastasis in 4 patients (2 %) were determined. There wasn't correlation between brain and bone metastasis and ischemic stroke (p = 0,075, p = 0,169, p = 0,112, respectively). DISCUSSION and CONCLUSION: Cisplatin and docetaxel use in patients with non-small cell lung cancer increase cerebrovascular diseases up to ten folds due to the cancer itself or side effects of treatments.

Sisplatin ve Dosetaksel Kullanan Küçük Hücreli Dışı Akciğer Kanserli Hastalarda İnme Sıklığının Değerlendirmesi

GİRİŞ ve AMAÇ: İnme, beyin damar hastalığını takip ederek ortaya çıkan klinik bir durumu, ani bir nörolojik yetersizliği ifade eder ve hasarın patolojisine göre iskemik ve kanayıcı olarak iki alt gruba ayrılır. Sisplatin ve dosetaksel çeşitli kanserlerin tedavisinde kullanılan bir ilaçtır. Bizim bu çalışmadaki amacımız, sisplatin ile birlikte dosetaksel alan küçük hücre dışı akciğer kanseri hastalarında tedavi esnasında veya sonrasında inme sıklığını araştırmaktı. YÖNTEM ve GEREÇLER: Tıbbi Onkoloji Kliniği’nde küçük hücre dışı akciğer kanseri tanısı olan ve 21 günde bir en az 6 kür sisplatin 75mg/m2 ile birlikte dosetaksel 75mg/m2 tedavisi alan ve 18 yaşından büyük hastalar ileriye dönük olarak 6 ay süre ile takip edildi. Çalışmaya alınan hastaların ne zaman tanı aldığı, metastazı olup olmadığı sorgulandı ve nörolojik muayenesi yapıldı. İlaç tedavisi tamamlandığında hastaların tedavi esnasında ve sonrasında inme geçirip geçirmediği, inme geçirdi ise türü (hemorajik/iskemik) sorgulandı. BULGULAR: İzlem süresinde hastaların 6 (%3) tanesinde iskemik inme gelişti. Bu hastaların 4’ü (%2,3) erkek, 2’si (%7,7) kadındı. 61 (%31) hastada lenf nodu, 25 (%12,7) hastada beyin, 24 (%12,2) hastada kemik, 7 (%3,6) hastada sürrenal, 4 (%2) hastada karaciğer metastazı saptandı. Beyin ve kemik metastazı olması ile iskemik inme arasında ilişki saptanmadı (sırasıyla p=0,075, p=0,169, p=0,112). TARTIŞMA ve SONUÇ: Sisplatin ve dosetaksel alan küçük hücre dışı akciğer kanserli hastalarda kanserin kendisi ya da tedavilerin yan etkisi ile beyin damar hastalıkları neredeyse 10 kata kadar artmaktadır.

PDF

___

Adams Jr HP, Bendixen BH, Kappelle J, Biler J, Love BB, Gordon DL and the TOAST Investigators. Classification of subtype of acute ischemic stroke. Definition for use in multicenter clinical trial. Stroke 1993; 24: 35-41.

Special report from the World Healthy Organization. Stroke 1989. Report of the WHO Task Force on stroke and other cerebrovasculer disorder. Stroke 1989; 20: 1407-31.

Go RS, Adjei AA. Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin. JClin Oncol 1999;17(1): 409-22.

Go RS, Adjei AA. Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin. JClin Oncol 1999;17(1): 409-22.

Chen PC, Muo CH, Lee YT, Yu YH, Sung FC. Lung cancer and incidence of stroke: a populationbased cohort study. Stroke2011;42: 3034-9.

Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, Granetto C, Occelli M, Fea E, Heouaine A, Gasco M, Merlano M. Prospective Evaluation of Major Vascular Events in Patients with Nonsmall Cell Lung Carcinoma Treated with Cisplatin and Gemcitabine. Cancer. 2005;103: 994-9.

Li S, Chen W, TangY, RauK, Chen Y, Huang T, Liu J, Huang C. Incidence of ischemic stroke postchemotherapy: A retrospective review of 10963 patients Clin Neurol and Neurosur 2006: 108;150-6.

De Bruin ML, Dorresteijn LDA, van’t Veer MB, Krol ADG, van der Pal HJ, Kappelle AC, Boogerd W, Aleman BMP, van Leeuwen FE. Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma. J Natl Cancer Inst 2009;101: 928-37.

Zhang Y, Chapman A, Plested M, Jackson D, Purroy F. The Incidence, Prevalence, andMortality of Stroke in France, Germany, Italy, Spain, the UK, and the US: A Literature Review. Stroke Research and Treatment 2012;2012: 1-11.

Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta NeurolScand 2009: 119: 1-16.

Periard D, Boulanger CM, Eyer S et al. Are circulating endothelial-derived and plateletderived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke 2007;38: 1636-8.

Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular Neurotoxicity Following Chemotherapy with Cisplatin, Ifosfamide, and Etoposide. The Annals of Pharmacotherapy. 2004: 38;242-6.

Dehnee AE, Brizendine S, Herrera CJ. Recurrent strokes in a young patient with papillary fibroelastoma: a case report and literature review. Echocardiography 2006; 23: 592-5.

Tripodi A. D-dimertesting in laboratorypractice. ClinChem. 2011;57: 1256-62.

Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, Hennerici MG, Fatar M. Strokeandcancer. Theimportance of cancerassociated hypercoagulation as a possible stroke etiology. Stroke2012;43: 3029-34.

Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, Mochizuki H. Characteristics of cryptogenic stroke in cancer patients. AnnClinTranslNeur 2016;3(4):280-7.

Grazioli S, Paciaroni M, Agnelli G, Acciarresi M, Alberti A, D’Amore C, Caso V, Venti M, Guasti L, Ageno W. Cancer-associated ischemic stroke; A retrospective multicenter cohort study. ThrombRes2018;165:33-7.

Kim SG, Hong JM, Kim HY, Lee J, Chung P, Park K, Kim GM, Lee KH, Chung C, Bang OY, Ischemic Stroke in Cancer Patients With and Without Conventional Mechanisms A Multicenter Study in Korea. Stroke 2010;41; 798-801.

Zhamg YY, Chan DK, Cordato D, Shen Q, Sheng AZ. Stroke risk factor, pattern and outcome in patients with cancer. ActaNeurolScand2006;114: 378-83.